LQ-101

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLQ-101
Drug Alias NameLQ-101LQ101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-MUC1Gene transferenceCell replacements
TargetsMucin-1
Therapy Area/IndicationsCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCholangiocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A